Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)

Journal of Bone and Mineral Research

Volumn 27, Issue 8, 2012, Pages 1627-1634

  Jacques, Richard M ^a   Boonen, Steven ^b   Cosman, Felicia ^c   Reid, Ian R ^d   Bauer, Douglas C ^e   Black, Dennis M ^e   Eastell, Richard ^f  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c HELEN HAYES HOSPITAL   (United States)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

BONE MINERAL DENSITY; FRACTURE; PERCENT OF TREATMENT EFFECT EXPLAINED; PINP; SURROGATE; ZOLEDRONIC ACID

Indexed keywords

PLACEBO; PROCOLLAGEN C PROTEINASE; ZOLEDRONIC ACID;

AGED; ARTICLE; BONE DENSITY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FRACTURE REDUCTION; HIP; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIP; HUMANS; IMIDAZOLES; INCIDENCE; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; RISK FACTORS; SPINAL FRACTURES;

EID: 84864128180     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1644     Document Type: Article

References (19)

1. Marshall D, Johnell O, Wedel H,. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996 May 18; 312 (7041): 1254-9.
2. Bruyere O, Roux C, Badurski J, Isaia G, de Vernejoul MC, Cannata J, Ortolani S, Slosman D, Detilleux J, Reginster JY,. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin. 2007 Dec; 23 (12): 3041-5.
3. Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD, Fardellone P, Brixen K, Devogelaer JP, Diaz-Curiel M, Albanese C, Kaufman JM, Pors-Nielsen S, Reginster JY,. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocr Metab. 2007 Aug; 92 (8): 3076-81.
4. Sarkar S, Mitlak BH, Wong MM, Stock JL, Black DM, Harper KD,. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002 Jan; 17 (1): 1-10.
5. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD,. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate. J Clin Densitom. 2004; 7 (3): 255-61.
6. Watts NB, Geusens P, Barton IP, Felsenberg D,. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. 2005 Dec; 20 (12): 2097-104.
7. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu HL, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR,. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 May 3; 356 (18): 1809-22.
8. Black DM, Palermo L, Nevitt MC, Genant HK, Christensen L, Cummings SR,. Defining incident vertebral deformity: a prospective comparison of several approaches. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1999 Jan; 14 (1): 90-101.
9. Black DM, Palermo L, Nevitt MC, Genant HK, Epstein R, Sanvalentin R, Cummings SR,. Comparison of methods for defining prevalent vertebral deformities-the Study of Osteoporotic Fractures. J Bone Miner Res. 1995 Jun; 10 (6): 890-02.
10. Genant HK, Wu CY, Vankuijk C, Nevitt MC,. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993 Sep; 8 (9): 1137-48.
11. Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, Kendler D, Eriksen EF, Mesenbrink PG, Eastell R;, HORIZON-PFT Research Group. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res. 2009 Sep; 24 (9): 1544-51.
12. Li Z, Meredith MP, Hoseyni MS,. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med. 2001; 20 (21): 3175-88.
13. Lin DY, Fleming TR, DeGruttola V,. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med. 1997 Jul 15; 16 (13): 1515-27.
14. Wickham H,. ggplot2: elegant graphics for data analysis. New York: Springer; 2009.
15. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM,. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002 Mar; 112 (4): 281-9.
16. Miller PD, Delmas PD, Huss H, Patel KM, Schimmer RC, Adami S, Recker RR,. Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate. Calcif Tissue Int. 2010 Oct; 87 (4): 305-13.
17. Austin M, Yang YC, Vittinghoff E, Adami S, Boonen S, Bauer DC, Bianchi G, Bolognese MA, Christiansen C, Eastell R, Grauer A, Hawkins F, Kendler DL, Oliveri B, McClung MR, Reid IR, Siris ES, Zanchetta J, Zerbini CA, Libanati C, Cummings SR;, for the FREEDOM Trial. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2012 March; 27 (3): 687-93.
18. Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS,. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010 Oct; 25 (10): 2239-50.
19. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD,. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003 Jun; 18 (6): 1051-6.